Literature DB >> 6093789

Analysis of the apoC-II gene in apoC-II deficient patients.

S S Fojo, S W Law, D L Sprecher, R E Gregg, G Baggio, H B Brewer.   

Abstract

Apolipoprotein C-II (apoC-II), a 79 amino acid protein, is a cofactor for lipoprotein lipase, the enzyme which catalyzes the lipolysis of triglycerides on plasma chylomicrons and VLDL. Patients with apoC-II deficiency have marked elevations in plasma triglycerides, chylomicrons, VLDL, and a type I hyperlipoproteinemia. In order to evaluate the molecular defect in apoC-II deficiency, genomic DNA was analyzed using Southern Blot from 2 independent apoC-II deficient patients and compared to normal controls. Restriction digests of genomic DNA were performed with five different enzymes and the restriction fragments analyzed utilizing a 354 base pair nick-translated apoC-II probe for hybridization following Southern blotting. The restriction fragments varied from 0.8 to 21 Kb, and the pattern with normal DNA was identical to that of the two apoC-II deficient patients. The present study reveals that the apoC-II gene is present in patients with apoC-II deficiency. In addition, no insertional or deletional polymorphism was detected in the apoC-II gene of apoC-II deficient patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093789     DOI: 10.1016/0006-291x(84)90953-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity.

Authors:  O U Beg; M S Meng; S I Skarlatos; L Previato; J D Brunzell; H B Brewer; S S Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 3.  Diagnosis of genetic disease using recombinant DNA.

Authors:  D N Cooper; J Schmidtke
Journal:  Hum Genet       Date:  1986-05       Impact factor: 4.132

4.  Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency.

Authors:  S S Fojo; U Beisiegel; U Beil; K Higuchi; M Bojanovski; R E Gregg; H Greten; H B Brewer
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease.

Authors:  P W Connelly; G F Maguire; J A Little
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

6.  A novel type hypertriglyceridemia observed in FLS mice.

Authors:  Masaya Takahashi; Toshiji Saibara; Yoshihisa Nemoto; Masafumi Ono; Naoaki Akisawa; Shinji Iwasaki; Katsumi Toda; Yasuhiro Ogawa; Akihiko Wakatsuki; Shuichiro Inagaki; Saburo Onishi
Journal:  Lipids       Date:  2003-07       Impact factor: 1.880

7.  Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

Authors:  G Baggio; E Manzato; C Gabelli; R Fellin; S Martini; G B Enzi; F Verlato; M R Baiocchi; D L Sprecher; M L Kashyap
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

8.  Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein.

Authors:  P W Connelly; G F Maguire; T Hofmann; J A Little
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

9.  A deletion of one nucleotide results in functional deficiency of apolipoprotein CII (apo CII Toronto).

Authors:  D W Cox; D E Wills; F Quan; P N Ray
Journal:  J Med Genet       Date:  1988-10       Impact factor: 6.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.